New drug cocktail shows promise in Hard-to-Treat cancers
NCT ID NCT01582191
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 19 times
Summary
This early-stage trial tested a combination of two targeted drugs, vandetanib and everolimus, in 151 people with advanced cancers that had stopped responding to standard treatments. The main goals were to find the safest dose and see how well the drugs worked together to shrink tumors. The study focused on side effects and tumor response, offering a potential new option for patients with few alternatives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.